Site is Being Upgraded

 Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/January/2018, 11.34 am

Vitamin-based combinatorial therapy for reversing TIIDM: A pharmaceutical mixture encompassing Vitamin-B12  and Omega-3-fatty acids (VB12O3FA)  augments the expression of FGF19 and FGF1,   attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIIDM via up regulation of its target gene, 12/January/2017, 11.22 pm
January 12, 2018
Natural product-derived combinatorial therapy for therapy-resistant cancers: A therapeutic mix encompassing encompassing Shikonin, Idasanutlin, Rhamnetin, & Cisplatin [SIRC] inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via up regulation of its target gene, 12/January/2017, 11.45 pm
January 12, 2018
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:   Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene


From significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From research findings to Therapeutic opportunity: 

This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN)   may protect against cardiovascular diseases.

 ANNN, by decreasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration.  

Figure1. Mechanistic insights into how a pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN) may promote cardiac dedifferentiation and regeneration. ANNN, by increasing the expression of its target gene, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. The chemical structure of Aspalathin (AN) and Nothofagin (NN). ANNN may promote cardiac regeneration through induction of Her2/Erbb2

Thus, pharmacological formulations encompassing “Aspalathin (AN) and Nothofagin (NN)   or their analogues, either alone or in combination with other drugs “ may be used to promote cardiomyocyte regeneration following myocardial infarction


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How  a pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN) increases the expression of  ERBB2/Her2

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [ANNN] encompassing  Aspalathin (AN) and Nothofagin (NN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 12/January/2018, 11.34 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.